Pharvaris N.V.
deucrictibant XR
HAE attacks
Countdown
86days
Phase 3 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 3 trial results for deucrictibant XR in HAE attacks are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 10h ago
“Pharvaris anticipates announcing topline data from CHAPTER-3 in the third quarter of 2026.”